{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:54:02Z","timestamp":1774972442774,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T00:00:00Z","timestamp":1238025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sunitinib inhibits KIT and other members of the split\u2010kinase\u2010domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib\u2010resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Sunitinib therapy was provided through a treatment\u2010use protocol. Patients were 10\u201317 years old at enrollment. All patients had GIST resistant to imatinib therapy. Sunitinib was administered daily for 4 weeks in 6\u2010week treatment cycles. <jats:italic>KIT<\/jats:italic> and platelet\u2010derived growth factor receptor alpha (<jats:italic>PDGFRA<\/jats:italic>) genotyping of tumor tissue were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One patient achieved a partial response, five patients had stable disease and one patient had progressive disease on sunitinib. The duration of disease stabilization was between 7 and 21+ months, with a mean of 15 months. Time to tumor progression was longer on sunitinib than on prior imatinib treatment for five of six patients. Two patients experienced grade 3 adverse events. All other adverse events were grade 1\u20132. None of the five patients tested had mutations in <jats:italic>KIT<\/jats:italic> or <jats:italic>PDGFRA<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib\u2010resistant GIST. Pediatr Blood Cancer 2009;52:767\u2013771. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21909","type":"journal-article","created":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T16:29:59Z","timestamp":1238084999000},"page":"767-771","source":"Crossref","is-referenced-by-count":129,"title":["Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib"],"prefix":"10.1002","volume":"52","author":[{"given":"Katherine A.","family":"Janeway","sequence":"first","affiliation":[]},{"given":"Karen H.","family":"Albritton","sequence":"additional","affiliation":[]},{"given":"Annick D.","family":"Van Den Abbeele","sequence":"additional","affiliation":[]},{"given":"Gina Z.","family":"D'Amato","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[]},{"given":"James E.","family":"Butrynski","sequence":"additional","affiliation":[]},{"given":"Marcus","family":"Schlemmer","sequence":"additional","affiliation":[]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[]},{"given":"George D.","family":"Demetri","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2009,3,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079666"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.190"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9177-7"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69446-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1938"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1984"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000172190.79552.8b"},{"key":"e_1_2_6_11_2","first-page":"471","article-title":"SU11248 inhibits KIT and platelet\u2010derived growth factor receptor \u03b2 in pre\u2010clinical models of human small cell lung cancer","volume":"2","author":"Abrams TJ","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2307"},{"key":"e_1_2_6_13_2","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet\u2010derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel DB","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0204183"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2845"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:CLIN.0000006873.65590.68"},{"key":"e_1_2_6_17_2","unstructured":"NCCN Soft Tissue Sarcoma Panel.NCCN practice guideline in oncology: Soft tissue sarcoma v.2.2008. National Comprehensive Cancer Network 2008.http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7461"},{"key":"e_1_2_6_19_2","unstructured":"Cancer Therapy Evaluation Program.Common terminology criteria for adverse events (CTCAE) version 3.0. Bethesda MD: National Cancer Institute 2003.http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61103-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4403"},{"key":"e_1_2_6_23_2","first-page":"362a","article-title":"For the GIST Collaborative PET Study Group (Dana\u2010Farber Cancer Institute, Boston, Massachusetts; OHSU, Portland, Oregon; Helsinki University Central Hospital, Turku University Central Hospital, Finland: Novartis Oncology). F18\u2010FDG\u2010PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST)","volume":"20","author":"Van den Abbeele AD","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22214"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2285"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)80604-9"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.2496"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20352"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-005-1511-9"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-9-200611070-00008"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21909","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:49:25Z","timestamp":1696934965000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,26]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1002\/pbc.21909"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21909","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,26]]}}}